Novozymes A/S (OTCMKTS:NVZMY) Stock Passes Above 50-Day Moving Average – Time to Sell?

Shares of Novozymes A/S (OTCMKTS:NVZMY) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $60.57 and traded as high as $65.79. Novozymes A/S shares last traded at $65.52, with a volume of 17,315 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NVZMY shares. Rothschild & Co Redburn upgraded Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. Kepler Capital Markets upgraded Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, Zacks Research raised Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Novozymes A/S Stock Down 1.1%

The stock has a 50 day simple moving average of $60.67 and a 200 day simple moving average of $60.47. The company has a quick ratio of 1.03, a current ratio of 1.67 and a debt-to-equity ratio of 0.27. The stock has a market cap of $26.87 billion, a price-to-earnings ratio of 43.80, a PEG ratio of 3.06 and a beta of 0.92.

Novozymes A/S (OTCMKTS:NVZMY) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.32 billion. Novozymes A/S had a net margin of 14.22% and a return on equity of 6.52%. As a group, analysts expect that Novozymes A/S will post 2.43 earnings per share for the current fiscal year.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).